HDACis have been shown to increase PD-L1 expression in several tumors, including breast cancer, melanoma, HCC, soft tissue sarcoma, and B-cell lymphoma, thereby improving the efficacy of immunotherapy (33, 149, 150). The gene discussed is CD274; the disease is B-cell non-Hodgkin lymphoma.